Eli Lilly's GLP-1 growth

Kim Kahn summarizes Eli Lilly's strong Q4, with Manjaro and Zepbound revenues more than doubling year-over-year.

Play episode from 01:20

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!